The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)

Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2022-05, Vol.126 (9), p.1346-1354
Main Authors: Eichler, Martin, Singer, Susanne, Hentschel, Leopold, Richter, Stephan, Hohenberger, Peter, Kasper, Bernd, Andreou, Dimosthenis, Pink, Daniel, Jakob, Jens, Grützmann, Robert, Fung, Stephen, Wardelmann, Eva, Arndt, Karin, Heidt, Vitali, Bonilla, Sergio Armando Zapata, Gaidzik, Verena I., Jambor, Helena K., Weitz, Jürgen, Schaser, Klaus-Dieter, Bornhäuser, Martin, Schmitt, Jochen, Schuler, Markus K.
Format: Article
Language:English
Subjects:
692/4028/67/1344
692/4028/67/1798
Adult
Appetite loss
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Drug Resistance
Epidemiology
Humans
Medical prognosis
Molecular Medicine
Observational studies
Oncology
Patients
Prognosis
Public health
Quality of Life
Risk factors
Sarcoma
Soft Tissue Neoplasms
Surveys and Questionnaires
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult sarcoma patients from 2017 to 2020 in 39 German recruiting sites using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Vital status was ascertained over the course of 1 year. HRQoL domains were analysed by multivariable cox-regressions including clinical and socio-economic risk factors. Results Of 1102 patients, 126 (11.4%) died during follow-up. The hazard ratio (HR) for global health was 0.73 per 10-point increase (95% confidence interval (CI) 0.64–0.85). HR for the HRQoL-summary score was 0.74 (CI 0.64–0.85) and for physical functioning 0.82 (CI 0.74–0.89). There was also evidence that fatigue (HR 1.17, CI 1.10–1.25), appetite loss (HR 1.15, CI 1.09–1.21) and pain (HR 1.14, CI 1.08–1.20) are prognostic factors for survival. Conclusion Our study adds sarcoma-specific evidence to the existing data about cancer survival in general. Clinicians and care-givers should be aware of the relations between HRQoL and survival probability and include HRQoL in routine assessment.
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-022-01702-z